The New England journal of medicine · 2016 · Clinical trial · PMID 27633186
Explore the library
Strong human evidenceGLP-1 receptor agonist
Semaglutide
Semaglutide is a peptide GLP-1 analog used in several FDA-approved finished medications. Product names, formulations, indications and eligible populations differ.
Also indexed as: Ozempic · Wegovy · Rybelsus
A clear starting point
Semaglutide is a peptide GLP-1 analog used in several FDA-approved finished medications. Product names, formulations, indications and eligible populations differ.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
GLP-1 signaling
Semaglutide is a peptide GLP-1 analog used in several FDA-approved finished medications. Product names, formulations, indications and eligible populations differ.
- Targets & processes
- GLP-1 signaling
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Glycemic, weight and cardiovascular outcomes in defined patient groups.
What this does not establish
Randomized trials establish specific outcomes in selected populations. They do not validate unapproved formulations, every proposed use or self-treatment.
The New England journal of medicine · 2021 · Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't · PMID 33567185
Verified sample: 1,961 · Adults with overweight or obesity without diabetes
Greater average weight reduction at 68 weeks; gastrointestinal effects were common.
Limitations: Product-, population- and protocol-specific; does not imply suitability for an individual.
The New England journal of medicine · 2023 · Clinical trial · PMID 37952131
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
Label warnings include thyroid C-cell tumors observed in rodents (human relevance unknown), pancreatitis, gallbladder disease, severe GI effects and dehydration-related kidney injury. Contraindicated with personal/family MTC or MEN2 or serious hypersensitivity. Weight-loss use is inappropriate in pregnancy.
Contraindications & cautions
Not an exhaustive contraindication review. Label warnings include thyroid C-cell tumors observed in rodents (human relevance unknown), pancreatitis, gallbladder disease, severe GI effects and dehydration-related kidney injury. Contraindicated with personal/family MTC or MEN2 or serious hypersensitivity. Weight-loss use is inappropriate in pregnancy.
Medication & supplement interactions
Interaction information is incomplete. Label warnings include thyroid C-cell tumors observed in rodents (human relevance unknown), pancreatitis, gallbladder disease, severe GI effects and dehydration-related kidney injury. Contraindicated with personal/family MTC or MEN2 or serious hypersensitivity. Weight-loss use is inappropriate in pregnancy.
Regulatory status · United States
FDA-approved products · specific indications. Ozempic, Rybelsus and Wegovy have product-specific FDA approvals. Indications and eligible populations differ; consult the current label. Approval does not extend to research preparations.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
IW Interactive Learning Engine · 5 minutesGLP-1: from receptor to evidence
Explore the pathway & test your understandingYour scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.